Johnson & Johnson's Ottava Robotic Surgery System Meets Key Milestone in Clinical Trial
Johnson & Johnson announced that its investigational Ottava robotic surgery system met primary endpoints in a clinical study for Roux-en-Y gastric bypass procedures. The results could support FDA clearance for multiple upper abdominal procedures, positioning J&J to compete in the robotic surgery market dominated by Intuitive Surgical.
Tickers: $AMZN $ARM $AVGO $DD $GLW $GOOGL $INTC $ISRG $JNJ $MU $Q $SNDK
Topics: AI infrastructure earnings report robotic surgery stock market technology stocks